Grefixyl (Brinzolamide, Brimonidine Tartrate)

Grefixyl is indicated for the treatment of conditions characterized by elevated intraocular pressure.

• Open-angle glaucoma, where reduction of intraocular pressure helps preserve visual field.
• Ocular hypertension, to lower pressure and reduce risk of progression to glaucoma.
• Patients who require a dual mechanism approach, combining carbonic anhydrase inhibition with alpha-2 adrenergic activity.
• Situations where monotherapy has been insufficient, allowing a single eye drop to replace multiple agents.
• Use as adjunct therapy when surgical or laser interventions are not indicated.
• Management of patients who cannot tolerate systemic carbonic anhydrase inhibitors, offering a localized ocular formulation.

The ocular safety profile of Grefixyl includes both frequently observed and less common reactions. Most patients experience only mild, short‑lasting symptoms, and the majority of adverse events resolve without intervention.

Common

• Transient eye irritation or burning sensation that typically resolves within a few minutes after instillation.
• Temporary blurred vision lasting a short period, usually clearing as the drop disperses.
• Mild conjunctival hyperemia (redness) without pain or discharge.
• Slight increase in tear production causing occasional watery eyes.

Serious

• Persistent ocular pain or a severe headache that does not improve with over‑the‑counter analgesics.
• Acute allergic reaction presenting with swelling of the eyelids, periorbital area, or conjunctiva.
• Significant decrease in visual acuity requiring prompt ophthalmic evaluation.
• Intraocular inflammation (uveitis) that may be accompanied by photophobia and requires medical treatment.

When prescribing Grefixyl, clinicians should evaluate patient history and ocular condition to minimize risk.

• Assess for hypersensitivity to brinzolamide, brimonidine, or any component of the formulation before initiating therapy.
• Use caution in patients with severe renal impairment, as brinzolamide is eliminated renally.
• Monitor intraocular pressure regularly after starting treatment to confirm therapeutic response.
• Avoid concurrent use with other topical ocular medications that may cause additive ocular surface irritation.
• Advise patients to report any persistent eye pain, vision changes, or signs of allergic reaction promptly.
• Consider discontinuation if significant systemic side effects such as hypotension or fatigue develop.

Grefixyl may interact with other ophthalmic or systemic agents, influencing efficacy or safety. Consider the following potential interactions when planning a treatment regimen.

Avoid

• Concomitant use with other carbonic anhydrase inhibitor eye drops, which can increase the risk of systemic acidosis.
• Simultaneous administration of topical beta‑blocker glaucoma medications, which may lead to excessive reduction of intraocular pressure.
• Use with systemic carbonic anhydrase inhibitors (e.g., acetazolamide) due to additive pharmacologic effects.

Use with caution

• Co‑administration with other alpha‑2 agonists (e.g., clonidine) may potentiate systemic hypotensive effects.
• Use alongside ocular anesthetics or mydriatics, as they may alter drug absorption.
• Patients on antihypertensive therapy should be monitored for additive blood pressure lowering.